Upload
haven
View
21
Download
0
Tags:
Embed Size (px)
DESCRIPTION
#1008 New Strategies in Treatment of Lung Cancer. November 9 to 12 Patrick Ross, Jr. MD, PhD Assistant Professor of Surgery Division of Surgical Thoracic Oncology The Ohio State University Medical Center & The James Cancer Hospital and Solove Research Institute Gregory A. Otterson, MD - PowerPoint PPT Presentation
Citation preview
#1008New Strategies in Treatment of Lung Cancer
November 9 to 12
Patrick Ross, Jr. MD, PhDAssistant Professor of SurgeryDivision of Surgical Thoracic OncologyThe Ohio State University Medical Center &The James Cancer Hospital and Solove Research Institute
Gregory A. Otterson, MDAssociate Professor of Internal MedicineDivision of Hematology and OncologyThe Ohio State University Medical Center &The James Cancer Hospital and Solove Research Institute
Gregory A. Otterson, MDAssociate Professor of Internal Medicine
Division of Hematology and OncologyThe Ohio State University Medical Center &
The James Cancer Hospital and Solove Research Institute 11
Profile Profile
Mr. Perkins
• 55 year old male• Smoker• Hemoptosis• Photodynamic therapy• 2 cycles of chemotherapy
Diagnosis: Large T3 N2 tumor
Mr. Perkins
• 55 year old male• Smoker• Hemoptosis• Photodynamic therapy• 2 cycles of chemotherapy
Diagnosis: Large T3 N2 tumor 22
33
New Treatment Strategies InThe Treatment Of Lung Cancer
New Treatment Strategies InThe Treatment Of Lung Cancer
• Multimodality treatment for locally advanced NSCLC - Surgery - Radiation - Chemotherapy
• Novel agents - SCLC - antisense bcl2 - NSCLC - farnesyltransferase inhibitors
• Multimodality treatment for locally advanced NSCLC - Surgery - Radiation - Chemotherapy
• Novel agents - SCLC - antisense bcl2 - NSCLC - farnesyltransferase inhibitors 44
Lung Cancer Statistics,1999
Lung Cancer Statistics,1999
• Greatest cause of cancer death worldwide - 921,000 deaths worldwide - 158,900 US deaths (90,900 men, 68,000 women)
• 28% of US cancer deaths (14% cancer cases)
• Greatest cause of cancer death worldwide - 921,000 deaths worldwide - 158,900 US deaths (90,900 men, 68,000 women)
• 28% of US cancer deaths (14% cancer cases)
55
Lung Cancer Treatment -Stage And Type SpecificLung Cancer Treatment -Stage And Type Specific
• Non-small cell lung cancer (NSCLC) - ~80% of lung cancer - Principally surgically treated - Chemotherapy and radiation therapy added in specific circumstances
• Small cell lung cancer (SCLC) - ~20% of lung cancer - Principally chemotherapy +/- radiation therapy
• Non-small cell lung cancer (NSCLC) - ~80% of lung cancer - Principally surgically treated - Chemotherapy and radiation therapy added in specific circumstances
• Small cell lung cancer (SCLC) - ~20% of lung cancer - Principally chemotherapy +/- radiation therapy 66
Locally Advanced NSCLC Locally Advanced NSCLC
• Stage IIIB - Generally unresectable - Either bulky primary tumor involving critical mediastinal structures, pleural effusion or contralateral mediastinal lymph node involvement
• Chemotherapy added to radiation therapy improves control and survival - Concurrent vs. sequential?
• Stage IIIB - Generally unresectable - Either bulky primary tumor involving critical mediastinal structures, pleural effusion or contralateral mediastinal lymph node involvement
• Chemotherapy added to radiation therapy improves control and survival - Concurrent vs. sequential?
77
Locally Advanced NSCLC Locally Advanced NSCLC
• Stage IIIA - Theoretically resectable - Ipsilateral mediastinal lymph nodes involved
• Surgery is principal modality in most centers - Post-operative radiation improves local controls
- Post-operative chemotherapy has not been dramatically successful
• Stage IIIA - Theoretically resectable - Ipsilateral mediastinal lymph nodes involved
• Surgery is principal modality in most centers - Post-operative radiation improves local controls
- Post-operative chemotherapy has not been dramatically successful
88
Stage IIIA NSCLC Stage IIIA NSCLC
• Questions asked in clinical trials - ? Pre-op chemotherapy - ? Pre-op radiation therapy - ? Pre-op chemo-radiotherapy - ? Role of surgery
• These questions remain open
• Questions asked in clinical trials - ? Pre-op chemotherapy - ? Pre-op radiation therapy - ? Pre-op chemo-radiotherapy - ? Role of surgery
• These questions remain open
99
Stage IIIA NSCLC Stage IIIA NSCLC
• Balance risks with benefits of aggressive treatment - Improved local / systemic control - Increased treatment related morbidity and mortality with combined treatment
• Prognostic / treatment factors - Weight loss (5-10%), performance status, age, comorbid conditions
• Balance risks with benefits of aggressive treatment - Improved local / systemic control - Increased treatment related morbidity and mortality with combined treatment
• Prognostic / treatment factors - Weight loss (5-10%), performance status, age, comorbid conditions
1010
OSU Trial For ResectableStage IIIA NSCLC
OSU Trial For ResectableStage IIIA NSCLC
• Pre-operative chemotherapy for three cycles (paclitaxel and carboplatin)
• Pre-operative radiation (to 4500 cGy) with a novel (Gadolinium-Texaphyrin) radiation sensitizer
• Curative resection planned after completion of radiation
• If incomplete resection, post-op radiation
• Pre-operative chemotherapy for three cycles (paclitaxel and carboplatin)
• Pre-operative radiation (to 4500 cGy) with a novel (Gadolinium-Texaphyrin) radiation sensitizer
• Curative resection planned after completion of radiation
• If incomplete resection, post-op radiation1111
Novel Drug Strategies Novel Drug Strategies
• Apoptosis - many chemotherapeutic drugs induce cell death by initiating a cellular suicide pathway in cancer cells (called apoptosis)
• Some cancers (including most SCLC) overexpress an oncogene (bcl2) that protects cells from apoptosis
• Apoptosis - many chemotherapeutic drugs induce cell death by initiating a cellular suicide pathway in cancer cells (called apoptosis)
• Some cancers (including most SCLC) overexpress an oncogene (bcl2) that protects cells from apoptosis
1212
Bcl2 Family Of Proteins Bcl2 Family Of Proteins
• Family of proteins that are involved in apoptotic pathways (some pro-, others anti-apoptotic)
• Bcl2 family members can homo- and hetero-dimerize with each other
• Susceptibility to programmed cell death (apoptosis) depends on relative ratio of homo- and hetero-dimers
• Family of proteins that are involved in apoptotic pathways (some pro-, others anti-apoptotic)
• Bcl2 family members can homo- and hetero-dimerize with each other
• Susceptibility to programmed cell death (apoptosis) depends on relative ratio of homo- and hetero-dimers
1313
1414
Bcl2 Antisense Therapy Bcl2 Antisense Therapy
• Chemotherapy induces cell death through apoptosis
• Bcl2 protects cells from apoptotic death
• In theory, chemotherapy should be more effective if bcl2 is inhibited
• Therefore, use bcl2 antisense (synthetic oligonucleotide directed against the bcl2 messenger RNA molecule)
• Chemotherapy induces cell death through apoptosis
• Bcl2 protects cells from apoptotic death
• In theory, chemotherapy should be more effective if bcl2 is inhibited
• Therefore, use bcl2 antisense (synthetic oligonucleotide directed against the bcl2 messenger RNA molecule) 1515
1616
Bcl2 Antisense In SCLC Bcl2 Antisense In SCLC
• Patient population: resistant SCLS (Either progressive disease on treatment or relapse within 3 months)
• G3139 (bcl2 antisense) via continuous IV infusion X 7 days
• Paclitaxel 175 mg / m2 over 3 hours, day 6 q 3 weeks
• Patient population: resistant SCLS (Either progressive disease on treatment or relapse within 3 months)
• G3139 (bcl2 antisense) via continuous IV infusion X 7 days
• Paclitaxel 175 mg / m2 over 3 hours, day 6 q 3 weeks
1717
Novel Drug Strategies Novel Drug Strategies
• Ras is an oncogene that is mutated in many different cancers (~90% of pancreatic ca, ~50% of colon ca and ~30% of NSCLC)
• Ras (normal and mutant) requires association with the cell membrane via a cholesterol precurser for activity
• Ras is an oncogene that is mutated in many different cancers (~90% of pancreatic ca, ~50% of colon ca and ~30% of NSCLC)
• Ras (normal and mutant) requires association with the cell membrane via a cholesterol precurser for activity
1818
1919
Inhibit Ras Activity ThroughIts Membrane Association
Inhibit Ras Activity ThroughIts Membrane Association
• HMG-CoA reductase inhibitors were attempted without remarkable success• Inhibition of the farnesyl-transferase enzyme has been pursued with better pre-clinical ad early clinical activity
• Single agent and combination trials are now underway (including one at OSU)
• HMG-CoA reductase inhibitors were attempted without remarkable success• Inhibition of the farnesyl-transferase enzyme has been pursued with better pre-clinical ad early clinical activity
• Single agent and combination trials are now underway (including one at OSU) 2020
Improvement InLung Cancer Survival?
Improvement InLung Cancer Survival?
• Better local control - Improved surgical technique - Improved preparation / selection of surgical patients - Improved radiotherapy technique and radiation sensitizers
• Better local control - Improved surgical technique - Improved preparation / selection of surgical patients - Improved radiotherapy technique and radiation sensitizers
2121
Improvement InLung Cancer Survival?
Improvement InLung Cancer Survival?
• Better control of systemic disease - Application of current chemotherapeutic agents in combination with surgery and / or radiation therapy - Novel chemotherapeutic agents, designed to attack specific genetic defects in tumor cells (for example, bcl2 antisense and farnesyltransferase inhibitors)
• Better control of systemic disease - Application of current chemotherapeutic agents in combination with surgery and / or radiation therapy - Novel chemotherapeutic agents, designed to attack specific genetic defects in tumor cells (for example, bcl2 antisense and farnesyltransferase inhibitors) 2222
2323
Summary Summary
Mr. PerkinsDiagnosis: IIIA non-small lung cancer
Treatment: - Photodynamic therapy - Chemotherapy - Right pneumonectomy
Follow-up: - Operation went smoothly - Further radiation and chemotherapy
Prognosis: Good
Mr. PerkinsDiagnosis: IIIA non-small lung cancer
Treatment: - Photodynamic therapy - Chemotherapy - Right pneumonectomy
Follow-up: - Operation went smoothly - Further radiation and chemotherapy
Prognosis: Good 2424
Patrick Ross, Jr. MD, PhDAssistant Professor of Surgery
Division of Surgical Thoracic OncologyThe Ohio State University Medical Center &
The James Cancer Hospital and Solove Research Institute 2525
Profile Profile
Joseph Tigerina• 61 year old male• Former smoker
• Newly identified left upper lobe mass
• Presented to family physician with left shoulder and back pain
Joseph Tigerina• 61 year old male• Former smoker
• Newly identified left upper lobe mass
• Presented to family physician with left shoulder and back pain
2626
Profile Profile
Joseph TigerinaSymptoms - No cough or hemoptsis - Some fatigue - No weight lossEvaluation - CT scan and CT needle guided biopsy - MRI - PET scanDiagnosis: Non small cell carcinoma
Joseph TigerinaSymptoms - No cough or hemoptsis - Some fatigue - No weight lossEvaluation - CT scan and CT needle guided biopsy - MRI - PET scanDiagnosis: Non small cell carcinoma
26-A26-A
2727
Non Small CellLung Cancer
Non Small CellLung Cancer
• Can the tumor be resected?• Can the patient undergo resection?• What can be done to improve the outcome?
• Can the tumor be resected?• Can the patient undergo resection?• What can be done to improve the outcome?
2828
2929
NSCLC: DiagnosisAnd Staging
NSCLC: DiagnosisAnd Staging
• Chest x-ray• CT scan chest• Distant metastasis evaluation• Bronchoscopy• Trans thoracic needle biopsy• Mediastinoscopy• VATS
• Chest x-ray• CT scan chest• Distant metastasis evaluation• Bronchoscopy• Trans thoracic needle biopsy• Mediastinoscopy• VATS 3030
Solitary Pulmonary Nodule:PET Scan
Solitary Pulmonary Nodule:PET Scan
3131
Surgical ManagementOf Stage 1 And 2
Surgical ManagementOf Stage 1 And 2
• Wedge resection vs lobectomy• Node sampling N1 and N2• Refer for adjuvant trials: evaluation of chemotherapy for early stage• Appropriate surveillance
• Wedge resection vs lobectomy• Node sampling N1 and N2• Refer for adjuvant trials: evaluation of chemotherapy for early stage• Appropriate surveillance
3232
Superior Sulcus TumorsSuperior Sulcus Tumors
• Arm pain • Arm parathesias
• Shoulder pain• Horner’s syndrome
• Arm pain • Arm parathesias
• Shoulder pain• Horner’s syndrome
3333
3434
3535
NSCLC Induction Therapy:Stage IIIA
NSCLC Induction Therapy:Stage IIIA
• Surgical staging
• Chemo or Radiation/chemo• Evaluate for distant disease• Nutrition
• Pulmonary rehab
• Surgical staging
• Chemo or Radiation/chemo• Evaluate for distant disease• Nutrition
• Pulmonary rehab
3636
Induction Therapy Induction Therapy
• Radiation alone
• Chemotherapy alone
• Radiation and chemotherapy: simultaneous vs sequential
• Radiation, and / or chemotherapy with PDT
• Pulmonary rehabilitation
• Radiation alone
• Chemotherapy alone
• Radiation and chemotherapy: simultaneous vs sequential
• Radiation, and / or chemotherapy with PDT
• Pulmonary rehabilitation3737
3838
3939
4040
4141
4242
Pulmonary Resection InThe High Risk Patient
Pulmonary Resection InThe High Risk Patient
• FEV 1 < 0.8• Hypoxemia• Hypercarbia• Steroid dependent• Elderly• Previous pulmonary resection
• FEV 1 < 0.8• Hypoxemia• Hypercarbia• Steroid dependent• Elderly• Previous pulmonary resection
4343
Pulmonary RehabilitationPulmonary Rehabilitation
• Prepare patient for resection • Decrease hospital stay• Enhance recovery• Promote sense of well being• Minimize impact of chronic illness
• Prepare patient for resection • Decrease hospital stay• Enhance recovery• Promote sense of well being• Minimize impact of chronic illness
4444
4545
4646
4747
4848
4949
5050
Summary Summary
Joseph Tigerina
Surgical procedure - Left upper lobe resection for non small cell cancer - Stage 1b lesion - all nodes were negative
Joseph Tigerina
Surgical procedure - Left upper lobe resection for non small cell cancer - Stage 1b lesion - all nodes were negative
5151
Summary Summary
Joseph Tigerina
Follow-up treatment• Given staging, treatment options are: - Surveillance - Adjunctive chemotherapy within a defined protocol
Prognosis: Good
Joseph Tigerina
Follow-up treatment• Given staging, treatment options are: - Surveillance - Adjunctive chemotherapy within a defined protocol
Prognosis: Good 51-A51-A
#1009 Evaluation & Management of Atrial Fibrillation
November 16 to 19
Stephen F. Schaal, MDProfessor of Internal MedicineDivision of CardiologyThe Ohio State University Medical Center
Robert Hoover, MDAssistant Professor of Internal MedicineDivision of CardiologyThe Ohio State University Medical Center
NEXT WEEK